Compare Enveric Biosciences Inc (ENVB) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Target Corporation — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Target Corporation trades at $140.05 (market cap $62.81B). The key difference: Target Corporation is far larger — about 11806.4× Enveric Biosciences Inc's market cap, and Target Corporation pays a 3.36% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | TGT | |
|---|---|---|
Market Cap | $5.32M | $62.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $141.19 |
52-Week Low | $1.28 | $83.68 |
Enterprise Value | $408.82K | $78.11B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Target (TGT) trades at $140.69, up 5.02% today, with strong technical momentum indicated by bullish moving averages. Recent earnings beats and a 3.24% net income margin highlight operational resilience, while a P/E of 18.27 and P/S of 0.59 suggest reasonable valuation. Positive news flow notes improving traffic trends from merchandising initiatives, supporting near-term optimism.
The outlook remains balanced with potential upside from execution on merchandising resets and consistent dividend payments, but risks include competitive pressures and margin volatility. Analyst consensus is mixed with a $137 price target slightly below current levels, indicating cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
